Explore

Trendline Trendline
Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology
Trendline Trendline
AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment

AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment

AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment
Trendline Trendline
Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma
Trendline Trendline
Andreas Goppelt Appointed Managing Director of OrphaCare to Drive Expansion

Andreas Goppelt Appointed Managing Director of OrphaCare to Drive Expansion

Andreas Goppelt Appointed Managing Director of OrphaCare to Drive Expansion
Trendline Trendline
Pharmaceutical Companies Announce Key Board Appointments to Strengthen Leadership

Pharmaceutical Companies Announce Key Board Appointments to Strengthen Leadership

Pharmaceutical Companies Announce Key Board Appointments to Strengthen Leadership
Trendline Trendline
Sapient Introduces Tumor Protein Mapping Platform to Enhance Cancer Treatment Insights

Sapient Introduces Tumor Protein Mapping Platform to Enhance Cancer Treatment Insights

Sapient Introduces Tumor Protein Mapping Platform to Enhance Cancer Treatment Insights
Trendline Trendline
Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026
Trendline Trendline
Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment

Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment

Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment
Trendline Trendline
AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal
Trendline Trendline
FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma

FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma

FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma
Trendline Trendline
Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026

Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026

Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026
Trendline Trendline
AbbVie Invests $1.4 Billion in North Carolina Manufacturing Campus to Boost Medicine Production

AbbVie Invests $1.4 Billion in North Carolina Manufacturing Campus to Boost Medicine Production

AbbVie Invests $1.4 Billion in North Carolina Manufacturing Campus to Boost Medicine Production